What are cheaper alternatives to Humira (adalimumab)?

Cheaper Alternatives to Humira (Adalimumab)

Adalimumab biosimilars are significantly cheaper alternatives to Humira with equivalent efficacy, safety, and immunogenicity profiles, making them the recommended cost-effective option for patients requiring this medication. 1

Available Adalimumab Biosimilars

The European Medicines Agency (EMA) has approved several adalimumab biosimilars that offer substantial cost savings compared to the originator Humira:

• Amgevita (ABP 501) - First FDA-approved adalimumab biosimilar 1
• Imraldi (SB5) 1
• Hyrimoz/Hefiya/Halimatoz (GP2017) 1
• Hulio (FKB327) 1
• Idacio/Kromeya (MSB11022) 1

Cost Comparison

Humira is one of the most expensive biologic medications on the market:

• Humira (adalimumab): Approximately $5,500-$5,800 per month 2
• Biosimilars: Generally priced 15-30% lower than the reference product, providing significant cost savings 2

Efficacy and Safety of Biosimilars

Multiple randomized controlled trials have demonstrated that adalimumab biosimilars have equivalent efficacy and safety profiles compared to the originator Humira:

• The VOLTAIRE-RA study showed that BI 695501 (adalimumab biosimilar) had similar ACR20 response rates at weeks 12 and 24 compared to Humira in rheumatoid arthritis patients 3
• Comprehensive physicochemical and functional analyses have confirmed high similarity between biosimilars like MSB11022 and HLX03 with Humira 4, 5
• Immunogenicity profiles (development of anti-drug antibodies) are comparable between biosimilars and the originator 3

Practical Considerations When Switching

When considering a switch from Humira to a biosimilar:

1. Formulation differences: Some biosimilars have different excipients, injection volumes, and needle sizes that may affect patient experience 1

   • Original Humira now has a citrate-free 40 mg/0.4 mL formulation with smaller needle (29 gauge)
   • Most biosimilars use 0.8 mL formulations with varying needle gauges (27-29)

2. No automatic substitution: In many countries, pharmacists cannot automatically substitute a biosimilar without consulting the prescribing physician 1

3. Patient education: Proper education about biosimilars is essential for patient acceptance and adherence 1

Algorithm for Selecting the Most Cost-Effective Option

1. For new patients: Start with the most affordable adalimumab biosimilar available in your region
2. For existing patients on Humira:
   • Discuss switching to a biosimilar, explaining equivalent efficacy and safety
   • Consider patient preference regarding injection device and formulation
   • Monitor clinical response after switching

Important Caveats

• The uptake of adalimumab biosimilars has been slower than expected in some regions despite their cost advantages 1
• Some patients may have insurance coverage or patient assistance programs that make Humira more affordable than biosimilars in certain situations
• The availability of specific biosimilars varies by country and region
• Switching between the originator and biosimilar has not shown any negative impact on efficacy, safety, or immunogenicity 3